Skip to main content

Nippon Shinyaku

Nippon Shinyaku Co Ltd is a Japanese pharmaceutical manufacturing enterprise developing prescription therapeutics and functional food ingredients. The company researches, produces, and commercializes pharmaceuticals for hematology, urology, rare genetic diseases, and musculoskeletal disorders, highlighted by Viltepso for Duchenne muscular dystrophy and Uptravi for pulmonary arterial hypertension. Main revenue drivers comprise global commercial sales of proprietary prescription pharmaceuticals, licensing milestone royalties, and functional food ingredient sales. Nippon Shinyaku serves urologists, hematologists, pediatric neurologists, hospital networks, and prescription pharmacies across Japan, North America, and Europe. The company holds a market-leading position in specialized treatments for rare neuromuscular diseases and urological conditions. Headquartered in Kyoto, Japan, Nippon Shinyaku Co Ltd is listed on the Tokyo Stock Exchange.

5 of the funds FundTelligence covers report a position in Nippon Shinyaku.

Legal name
Nippon Shinyaku Co Ltd
Sector
Health Care
Country
Japan
Funds holding it
5

Funds holding Nippon Shinyaku

Loading...